Skip to main content
. 2021 Jan 5;21:3. doi: 10.1186/s12885-020-07538-1

Table 2.

Constant HR estimatesa from a fixed-effects NMA of RFS/DFS in patients with resected stage II–IV melanoma

graphic file with name 12885_2020_7538_Tab2_HTML.jpg

aThe value in each cell represents the hazard ratio (95% credible interval) for the comparison of the treatment indicated in that row versus the treatment indicated in that column; bolded values are statistically significant at the 0.05 significance level

DFS disease-free survival, HR hazard ratio, IFN interferon, NMA network meta-analysis, RFS recurrence-free survival